Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Clinical characteristics and autoantibody profiles of patients at time of muscle biopsy a and results of immunohistochemical analysis of biopsies

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Immunohistochemical staining

Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Correlations between expression of receptors for BAFF and expression of markers for B and plasma cells, type I IFN production and plasmacytoid dendritic cells in muscle tissue a

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Expressing, Clinical Proteomics

Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Serial sections of muscle tissue mononuclear cell infiltrate. These sections were taken from a representative anti-Ro52/anti-Ro60-positive patient with polymyositis. They are immunohistochemically stained for B-cell marker CD19 (A) and plasma cell marker CD138 (E) . Original magnification, ×25. Details of infiltrate (original magnification, 1.25 × 25) stained for B cell–activating factor of the tumour necrosis factor family receptor (BAFF-R) (B) , B cell maturation antigen (BCMA) (C) , transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (D) , interferon α/β–inducible myxovirus resistance 1 (MX-1) protein (F) and plasmacytoid dendritic cell marker blood dendritic cell antigen 2 (BDCA-2) (G) compared to immunoglobulin G1 isotype control (H) . Brown colour indicates positively stained cells, indicated by arrows.

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Staining, Marker, Clinical Proteomics, Control

Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Immunofluorescent double-staining of B and plasma cells expressing receptors for B cell–activating factor of the tumour necrosis factor family in the muscle mononuclear cell infiltrate from a representative anti-Ro52/anti-60-positive patient with polymyositis. Immunofluorescence staining for plasma cell marker CD138 (red) and B cell maturation antigen (BCMA) (green) (A) in a tissue biopsy section from the same patient as in Figure (original magnification, ×200) with details (B) of staining for CD138, BCMA, 4′,6-diamidino-2-phenylindole (DAPI) and an overlay created with the confocal microscope (original magnification, ×600). Scattered CD19-positive cells were also present remote from the CD138-positive cells and were positive for BAFF-R (C) as expressed in details of CD19 (red), BAFF-R (green), DAPI (blue) and an overlay created with the confocal microscope (original magnification, ×600).

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Double Staining, Clinical Proteomics, Expressing, Immunofluorescence, Staining, Marker, Microscopy

Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Quantitative assessment of the expression of receptors for B cell–activating factor of the tumour necrosis factor family in muscle tissues. Cells positive for B cell–activating factor of the tumour necrosis factor family receptor (BAFF-R) (A) , B cell maturation antigen (BCMA) (B) or transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (C) per square millimetre of muscle tissue area are shown for healthy controls and patients with myositis with or without anti-Jo-1 and/or anti-Ro52/anti-Ro60 autoantibodies. IBM, Inclusion body myositis. Data presented are P- values calculated by Kruskal-Wallis (KW) test and Mann-Whitney (MW) U test. Horizontal bars represent medians for each group.

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Expressing, MANN-WHITNEY

Journal: Arthritis Research & Therapy

Article Title: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

doi: 10.1186/s13075-014-0454-8

Figure Lengend Snippet: Schematic illustration of suggested interaction of dendritic cells, type I interferon and local B cell differentiation in myositis muscle. Plasmacytoid dendritic cells (pDCs) stimulated by immunocomplexes produce type I interferon (IFN-α/β) and induce conventional dendritic cells (DCs) to secrete the cytokines B cell–activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL), which influence B cell differentiation and survival. Their three receptors—BAFF receptor (BAFF-R), B cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)—are differentially expressed during the maturation of B cells from naïve to memory B cells and plasma cell generation. Class switch, differentiation to plasmablast and survival are also enhanced by IFN-α/β. The presence of APRIL in myositis muscle is unclear, but its importance for immunoglobulin (Ig) class switch is known.

Article Snippet: Sections were stained overnight using primary antibodies towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2, final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final dilution 2 μg/ml), all kindly provided by ZymoGenetics (Seattle, WA, USA).

Techniques: Cell Differentiation, Clinical Proteomics

Journal: Frontiers in Immunology

Article Title: Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

doi: 10.3389/fimmu.2020.01986

Figure Lengend Snippet: A list of phage display-derived therapeutic antibodies that either are approved or have been investigated clinical trials.

Article Snippet: Ianalumab (VAY736, B-1239) , Defucosylated IgG1-κ , BAFF-R , Synthetic Fab ( , ) , Morphosys's HuCAL GOLD®/ POTELLIGENT® technology , Immunology ( – ) , CLL , Phase I , Novartis.

Techniques: Selection, Virus, Variant Assay, Binding Assay, Expressing

Journal: Arthritis Research & Therapy

Article Title: B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren’s syndrome: the similarities and differences

doi: 10.1186/ar4571

Figure Lengend Snippet: B cell phenotypes in IgG4-RD, pSS and healthy controls

Article Snippet: Peripheral blood mononuclear cells (PBMCs) from IgG4-RD, pSS, and HC were prepared according to standard Ficoll-Hypaque procedures (Pharmacia Biotech, Uppsala, Sweden), and were stained with PE-CY7-anti-CD19, FITC-anti-CD24, APC-anti-CD38, PE-anti-CD40, PE-anti-CD80, PE-anti-CD86, PE-anti-BAFF-R, PE-anti-TACI mAb (BD Biosciences, San Jose, CA, USA), and PE-anti-BCMA mAb (Biolegend, San Diego, CA, USA) or isotype-matched controls.

Techniques:

Journal: Arthritis Research & Therapy

Article Title: B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren’s syndrome: the similarities and differences

doi: 10.1186/ar4571

Figure Lengend Snippet: Expression of BAFF-R, CD40, CD80, and CD86 on peripheral B cells in IgG4-related disease (RD), primary Sjögren’s syndrome (pSS), and healthy controls (HC). Representative flow cytometry pictures of BAFF-R expression on CD19+ B cells of HC, IgG4-RD, and pSS patients (A) . Scatter plots showing the percentages of CD19 + BAFF-R + cells in CD19+ cells (B) . Scatter plots of the percentages of BAFF-R + expression on different B cell subsets (C-F) . The changes in mean fluorescence intensity (MFI) of BAFF-R from healthy subjects after stimulation with recombinant human BAFF (rhBAFF) for 48 h (G) . One representative example of decreased BAFF-R MFI on B cells by flow cytometry after 48 h culture in the presence of rhBAFF (2 ng/mL) (H) . Representative flow cytometry of CD40 expression on CD19+ B cells of HC, IgG4-RD, and pSS patients (I) . Scatter plots showing the percentages of CD19 + CD40+ cells in CD19+ cells (J-K) . Percentages of CD80 and CD86 expression on CD19+ B cells of HC, IgG4-RD, and pSS patients (L,M) . Values are shown as mean ± standard error of the mean, * P <0.05; ** P <0.01; *** P <0.001.

Article Snippet: Peripheral blood mononuclear cells (PBMCs) from IgG4-RD, pSS, and HC were prepared according to standard Ficoll-Hypaque procedures (Pharmacia Biotech, Uppsala, Sweden), and were stained with PE-CY7-anti-CD19, FITC-anti-CD24, APC-anti-CD38, PE-anti-CD40, PE-anti-CD80, PE-anti-CD86, PE-anti-BAFF-R, PE-anti-TACI mAb (BD Biosciences, San Jose, CA, USA), and PE-anti-BCMA mAb (Biolegend, San Diego, CA, USA) or isotype-matched controls.

Techniques: Expressing, Flow Cytometry, Fluorescence, Recombinant